Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Aug 27, 2012
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to assess knee movement and guide orthopedic surgeries with greater precision. The researchers are testing a system that combines special 3D imaging with minimally invasive techniques to help doctors perform knee surgeries more accurately. The goals of the study include measuring how well this new tool can track knee movement, ensuring that these measurements are consistent, and comparing the results of surgeries done with this tool to those performed using traditional methods. This could lead to better outcomes for patients undergoing knee surgeries for conditions like osteoarthritis or ligament injuries.
To participate in this trial, patients should be between the ages of 65 and 74 and be scheduled for specific knee surgeries, such as total knee replacement or ligament reconstruction. However, individuals with active infections, certain knee deformities, severe knee instability, or significant restrictions in knee movement may not be eligible. If you join the trial, you can expect to undergo the surgery using this innovative guidance system, which aims to improve both the process and your recovery experience.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients awaiting a knee surgery (total knee arthroplasty (TKA), high tibial osteotomy (HTO), anterior cruciate ligament reconstruction(ACLR))
- Exclusion Criteria:
- • Active infection
- • Atypical morphology and/or alignment of the lower limbs
- • Knee instability (other than secondary to ACL deficiency in patients awaiting ACLR)
- • Knee flexion contracture of 10 degrees or more
- • Knee flexion of less than 120 degrees
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Frédéric Lavoie, MD, MSc, FRCSC
Principal Investigator
CHUM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials